My submission to the Comments section of that arti
Post# of 72447
(Total Views: 528)
Posted On: 08/05/2020 12:26:15 PM
My submission to the Comments section of that article.
“Well written and I would add that those evaluating Brilacidin discovered a long time ago that it had antibiotic, antiviral, and antifungal capabilities. But limited funding has delayed investigation of its antiviral and antifungal capabilities. Fox Chase recently licensed the development of Brilacidin for anti-fungal uses and now Covid is prompting the accelerated development of its use to fight viruses. The company has already taken Brilacidin through Phase 2 testing for ABSSSI, Oral Mucocitis, and Ulcerative Proctitis with the compound proving to be efficacious in every instance. IPIX has executed a license agreement with Alfasigma S.p.A to develop and commercialize locally-administered (enema) Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. The Phase 1 trial for a time released pill has been completed. That time release pill is being developed for use against Ulcerative Colitis. In the Phase 2 ABSSSI trial, Brilacidin outperformed Daptomycin and did so with a single IV treatment. (Daptomycin is delivered as a 7 day IV regimen.) Brilacidin has been successful in every Phase 2 completed to date and now we know that it performs extremely well against SARS-CoV-2 in human lung cells lines (dose dependently destroying 90%, 95%, and 97% of the virus where Remdesivir only destroyed 50%) and also in human kidney cell lines (destroying 85%). Therefore, I think that it is highly likely that the upcoming Phase 2 trial for Covid-19 will also be successful. Further, Brilacidin’s MOA is such that it may also perform well on numerous other viruses.”
“Well written and I would add that those evaluating Brilacidin discovered a long time ago that it had antibiotic, antiviral, and antifungal capabilities. But limited funding has delayed investigation of its antiviral and antifungal capabilities. Fox Chase recently licensed the development of Brilacidin for anti-fungal uses and now Covid is prompting the accelerated development of its use to fight viruses. The company has already taken Brilacidin through Phase 2 testing for ABSSSI, Oral Mucocitis, and Ulcerative Proctitis with the compound proving to be efficacious in every instance. IPIX has executed a license agreement with Alfasigma S.p.A to develop and commercialize locally-administered (enema) Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. The Phase 1 trial for a time released pill has been completed. That time release pill is being developed for use against Ulcerative Colitis. In the Phase 2 ABSSSI trial, Brilacidin outperformed Daptomycin and did so with a single IV treatment. (Daptomycin is delivered as a 7 day IV regimen.) Brilacidin has been successful in every Phase 2 completed to date and now we know that it performs extremely well against SARS-CoV-2 in human lung cells lines (dose dependently destroying 90%, 95%, and 97% of the virus where Remdesivir only destroyed 50%) and also in human kidney cell lines (destroying 85%). Therefore, I think that it is highly likely that the upcoming Phase 2 trial for Covid-19 will also be successful. Further, Brilacidin’s MOA is such that it may also perform well on numerous other viruses.”
(12)
(0)